BAM
ITCI

Belpointe Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Belpointe Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,256
Closed -$68K – 3516
2023
Q1 		$68K Buy
1,256
+42
+3% +$2.03K ﹤0.01% 1537
2022
Q4 		$64.2K Buy
+1,214
New +$60.8K ﹤0.01% 1471

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Belpointe Asset Management's ITCI Position: Q2 2023 in Review

Belpointe Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2023, closing a stake of 1,256 shares — an estimated $68K sold.

Belpointe Asset Management first reported a position in ITCI in Q4 2022 and held it in 2 quarters. The position peaked at $68K in Q1 2023. 288 funds tracked by Wall St. Rank hold ITCI as of Q2 2023.

  • Belpointe Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 1,256 Intra-Cellular Therapies Inc. shares in Q2 2023, an estimated $68K.
  • Belpointe Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Intra-Cellular Therapies Inc. position peaked at $68K in Q1 2023.
  • 288 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.